The Journal of clinical psychiatry
-
Randomized Controlled Trial Comparative Study Clinical Trial
A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder.
The safety and antianxiety and antidepressive effects of buspirone (average 16.5 mg/day) were compared in a double-blind trial with those of diazepam (15 mg/day). The two drugs were nearly equivalent in relieving symptoms of both anxiety and depression in 100 patients. ⋯ Side effects, such as sedation and drowsiness, were significantly more frequent and severe with diazepam. Buspirone may be particularly indicated for anxious patients with associated depression.
-
Children who display sporadic unprovoked physical aggression and are refractory to usual treatment pose a difficult management problem. A group of 14 such children were matched with a control group; behaviors of both groups were observed and recorded for 3 months. ⋯ While on lithium, the children showed a substantial reduction in unprovoked aggressive outbursts. Because lithium was well tolerated and laboratory and clinical examinations did not show any adverse effects, it is suggested that lithium may be an important therapeutic agent in the treatment of aggression in children.
-
Case histories were reviewed of 25 patients with RDC diagnoses of schizophrenia or schizoaffective disorder who developed a clinical syndrome of depression subsequent to the resolution of their psychotic episodes. Of these patients, 14 were then treated with imipramine and 11 with amitriptyline in addition to their neuroleptic drugs. ⋯ Psychotic exacerbation was noted in only one patient. Imipramine seemed more beneficial than amitriptyline in these patients.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Viloxazine HCl in the treatment of endogenous depression: a standard (imipramine) controlled clinical study.
In a four week, double-blind clinical trial, 20 patients with endogenous depression were randomly assigned to treatment with either viloxazine or imipramine. Statistically significant improvement was observed on the Hamilton Psychiatric Rating Scales for Depression and Anxiety for both treatment groups. There were no differences between the two treatment groups in the type, incidence, or severity of treatment emergent symptoms. No medication-related abnormalities in clinical laboratory values occurred in either treatment group.